Company intelligence / Profile preview

F2G Solutions

Macclesfield, Cheshire, United Kingdomf2g.com ↗

Ownership: Private
Employees: ~72
Development stage: Other

Overview

F2G is developing a novel class of antifungals called orotomides. Their lead candidate, olorofim, targets fungal DHODH and has shown activity against rare and resistant mould infections. Olorofim has received orphan drug status from both the EMA and FDA for invasive aspergillosis and other rare invasive mould diseases. Clinical results to date indicate effectiveness in patients with limited treatment options.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Shionogi Co., Ltd. – collaboration for development/commercialization of novel antifungal agent olorofim in Asia-Pacific region

Beyond the preview

Go deeper on F2G Solutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F2G Solutions.